Haloperidol Depo Krka

Haloperidol Depo Krka is a prescription injectable formulation containing the antipsychotic active ingredient haloperidol. The product is supplied in a depot (long‑acting) preparation for intravascular administration, though specific strength and dosage form are not disclosed in the public data. It belongs to the butyrophenone class and is marketed within the European Union for the management of certain psychiatric conditions and is typically used under medical supervision.

Haloperidol Depo Krka is indicated for the treatment of several severe psychiatric disorders where long‑acting antipsychotic control is desired.

- Schizophrenia, including maintenance therapy for chronic cases. - Acute psychotic episodes that require rapid stabilization. - Manic episodes associated with bipolar disorder when oral therapy is insufficient. - Adjunctive treatment for patients with treatment‑resistant psychosis. - Situations where adherence to daily oral medication is a concern.

The safety profile of Haloperidol Depo Krka reflects its dopamine D2 antagonism and includes both frequent and rare reactions.

Common: - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Sedation or drowsiness. - Dry mouth and increased salivation. - Constipation or gastrointestinal discomfort. - Weight gain or changes in appetite.

Serious: - Neuroleptic malignant syndrome, a potentially life‑threatening condition. - Tardive dyskinesia with persistent involuntary movements. - Severe hypotension or cardiac arrhythmias. - Elevated prolactin leading to galactorrhea or menstrual disturbances.

Before initiating Haloperidol Depo Krka, clinicians should evaluate several patient‑specific factors to minimize risks.

- History of cardiovascular disease, including arrhythmias or prolonged QT interval. - Prior episodes of extrapyramidal reactions or tardive dyskinesia. - Current use of other central nervous system depressants or anticholinergic agents. - Liver or renal impairment that may affect drug clearance. - Pregnancy, lactation, or plans for conception, as safety data are limited. - Elderly patients, especially those with dementia‑related psychosis, due to increased sensitivity.

Haloperidol Depo Krka can interact with a range of medications; awareness of these interactions helps avoid adverse effects.

Avoid: - Other dopamine antagonists or high‑potency antipsychotics that may amplify extrapyramidal risk. - Drugs that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol levels.

Use with caution: - CYP3A4 inducers like carbamazepine or rifampin, which may reduce efficacy. - CNS depressants, including benzodiazepines and opioids, for additive sedation. - Anticholinergic medications that may mask early signs of extrapyramidal symptoms.